Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1171"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"route of administration: oral
study duration: quetiapine 300 mg bid and risperidone 3 mg bid for 7 consecutive days after titration periods of at least 17 days for quetiapine and two days for risperidone (see Figure 1). Risperidone was given after participant's quetiapine levels were considered to have reached steady state
population: 11 adults with schizophrenic, schizoaffective, or bipolar disorder (see NOTE below)
tested for known CYP450 polymorphisms? No
ages: 18 - 60
description:
Coadministration of risperidone resulted in only small
and statistically insignificant mean changes in quetiapine AUCtSS, CmaxSS, CminSS, and CL/f (Figure 2B, Table 3). Among individual patients, 6 of 11 patients had AUCtSS values that increased between days 17B and 5B, 3 had values that decreased, and 2 had values that changed very little.
NOTE: for some unknown reason, the authors calculated AUC and CL/f with data from 11 participants rather than all 12 participants who completed the study."
|
| dc:creator | |
| dc:date |
"09/22/2009 19:01:50"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ risperidone_increases_auc_quetiapine, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1063 }